N-Terminal domain antiandrogen
| N-Terminal domain antiandrogen | |
|---|---|
| Drug class | |
|  EPI-001, the first major N-terminal domain AR antagonist to be developed. | |
| Class identifiers | |
| Synonyms | N-Terminal domain AR antagonists; AR NTD antagonists | 
| Use | Prostate cancer | 
| Biological target | Androgen receptor | 
| Legal status | |
| In Wikidata | |
N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.
See also
References
| ARTooltip Androgen receptor | 
 | ||||||
|---|---|---|---|---|---|---|---|
| GPRC6A | 
 | ||||||
| 
 | |||||||
 
     This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.